Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Blood

Volumn 121, Issue 7, 2013, Pages 1165-1171

  Haso, Waleed ^a   Lee, Daniel W ^a   Shah, Nirali N ^a   Stetler Stevenson, Maryalice ^a   Yuan, Constance M ^a   Pastan, Ira H ^a   Dimitrov, Dimiter S ^b   Morgan, Richard A ^a   FitzGerald, David J ^a   Barrett, David M ^c   Wayne, Alan S ^a   MacKall, Crystal L ^a   Orentas, Rimas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Laboratory of Cancer Prevention   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CD22 CHIMERIC ANTIGEN RECEPTOR; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPITOPE; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOBLAST; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN MOTIF; SIGNAL TRANSDUCTION;

EID: 84874027123     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-438002     Document Type: Article

References (39)

1. Pui CH, Evans WE. Treatment of acute lympho-blastic leukemia. N Engl J Med. 2006;354(2):166-178.
2. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5): 532-543.
3. Wayne AS, Reaman GH, Helman LJ. Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008;100(18): 1271-1273.
4. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal Antibody-Based Therapies:A New Dawn in the Treatment of Acute Lymphoblastic Leukemia. J Clin Oncol. 2012;30(31):3876-3883.
5. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18(10):2780-2790.
6. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95): 95ra73.
7. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
8. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lym-phoma and normal B cells. Blood. 2010;116(19): 3875-3886.
9. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
10. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
11. Thomas DA, O'Brien S, Faderl S, et al. Chemoim-munotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-3889.
12. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol Rev. 2009;230(1):128-143.
13. Fitz Gerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with im-munotoxins and antibody-drug conjugates. Cancer Res. 2011;71(20):6300-6309.
14. Mansfield E, Amlot P, Pastan I, Fitz Gerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90(5):2020-2026. (Pubitemid 27377315)
15. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res. 2002;8(4):995-1002. (Pubitemid 35177347)
16. Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010;16(6):1894-1903.
17. Mussai F, Campana D, Bhojwani D, et al. Cyto-toxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblas-tic leukaemia. Br J Haematol. 2010;150(3):352-358.
18. Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS. Identification and characterization of fully human anti-CD22 monoclonal antibodies. mAbs. 2009;1(3): 297-303.
19. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689-702.
20. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem. 2005;280(1):607-617. (Pubitemid 40165027)
21. Zhao Y, Wang QJ, Yang S, et al. Aherceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced t lymphocytes and antitumor activity. J Immunol. 2009;183(9):5563- 5574.
22. Kreitman RJ, Pastan I. Antibody Fusion Proteins: Anti-CD22 recombinant immunotoxin moxetu-momab pasudotox. Clin Cancer Res. 2011; 17(20):6398-6405.
23. Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med. 2012;10:29.
24. Schwartz A, Marti GE, Poon R, Gratama JW, Fernandez-Repollet E. Standardizing flow cytom-etry: a classification system of fluorescence standards used for flow cytometry. Cytometry. 1998; 33(2):106-114. (Pubitemid 28447134)
25. Barrett DM, Seif AE, Carpenito C, et al. Noninva-sive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for pre-clinical modeling. Blood. 2011;118(15):e112-117.
26. Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scfvs and antigens. J Immunother. 2005;28(3):203-211. (Pubitemid 40593985)
27. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008;180(10):7028-7038.
28. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H. T cell activation by antibody-like immu-noreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173(12):7647-7653. (Pubitemid 39628207)
29. Tedder TF, Poe JC, Haas KM. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol. 2005; 88:1-50. (Pubitemid 41439747)
30. Brody J, Kohrt H, Marabelle A, Levy R. Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol. 2011;29(14):1864-1875.
31. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res. 2005; 11(4):1545-1550. (Pubitemid 40315239)
32. Stephan MT, Ponomarev V, Brentjens RJ, et al. 2007. T cell-encoded CD80 and 4-1BBL induce auto and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440-1449. (Pubitemid 350224246)
33. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cy-totoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol. 2002;20(2):143-148. (Pubitemid 34158029)
34. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453-1464.
35. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimu-latory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617- 4627.
36. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible co-stimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004; 172(1):104-113. (Pubitemid 38020461)
37. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatu-momab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
38. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-linage ALL. Blood. 2012; 120(6):5185-5187.
39. Morisot S, Wayne AS, Bohana-Kashtan O, et al. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lympho-blastic leukemias. Leukemia. 2010;24(11):1859-1866.